<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04233658</url>
  </required_header>
  <id_info>
    <org_study_id>2020-17</org_study_id>
    <nct_id>NCT04233658</nct_id>
  </id_info>
  <brief_title>Cynara Scolymus Extract for Treatment of Diabetes Mellitus Type 2</brief_title>
  <official_title>Cynara Scolymus Extract for Treatment of Diabetes Mellitus Type 2, a Pilot Clinical Trial Clinical Study Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stefan Fischli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Luzerner Kantonsspital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Edible parts of the artichoke plant (Cynara cardunculus, Cynara scolymus) are traditionally
      known in folk-medicine for lipid lowering and choleretic effects. Furthermore, antidiabetic
      effects are described. In the past year's research attributed health promoting effects to the
      main active compounds chlorogenic acid, luteolin and apigenin. Present literature indicates
      potential antidiabetic effects by different mechanisms like downregulation of
      gluconeogenesis, increased GLP-1 secretion and modification of insulin signalling. Up to now
      only few human clinical trials provide insufficient data to conclude the therapeutic
      potential of cynara scolymus extract in the treatment of type 2 diabetes.

      The primary objective is to evaluate the antidiabetic effect and the mechanisms of glucose
      lowering by a 12-week treatment with a highly-standardized extract of cynara scolymus in
      subjects with diabetes mellitus type 2 compared to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of HbA1c-level from baseline to week 12</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cynara Scolymus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>3x2 capsules / day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cynara Scolymus</intervention_name>
    <description>3x2 capsules / day</description>
    <arm_group_label>Cynara Scolymus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥18 years old.

          -  Diagnosis of diabetes mellitus type 2 ≥ 90 days prior to screening

          -  HbA1c-level between 6.5-9%

          -  Body mass index of ≥ 28 kg/m2

          -  Stable daily dose (for at least 30 days) of 1-3 oral antidiabetic drug (metformin,
             sulfonylurea, SGLT-2 inhibitor, thiazolidinedione or DPP-IV-inhibitor)

        Exclusion Criteria:

          -  Subjects with diabetes mellitus type 1 or history of ketoacidosis,

          -  Uncontrolled diabetes, defined as fasting plasma glucose ≥20mmol/l or recurrent
             hypoglycemia (defined as capillary glucose values ≤3.5mmol/l)

          -  Use of insulin or GLP-1-receptor agonists

          -  Women wanting to become pregnant

          -  Pregnant or breast-feeding women

          -  Known hepatic disorder

          -  Severe renal insufficiency (GFR ≤30ml/min)

          -  History of inflammatory bowel disease

          -  History of gastric bypass or gastric sleeve surgery

          -  Anticoagulation with vitamin K-antagonists
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 20, 2020</last_update_submitted>
  <last_update_submitted_qc>January 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Luzerner Kantonsspital</investigator_affiliation>
    <investigator_full_name>Stefan Fischli</investigator_full_name>
    <investigator_title>Deputy Head Division of Endocrinology and Diabetes</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

